Delhi HC asks SII, Bharat Biotech to disclose their manufacturing capacity

The high court also asked the Centre to explain in affidavit the rationale behind keeping strict control over class of persons who can be vaccinated against Covid-19

Covaxin
Press Trust of India New Delhi
2 min read Last Updated : Mar 04 2021 | 2:41 PM IST

The Delhi High Court Thursday directed Serum Institute of India and Bharat Biotech to disclose their capacities to manufacture Covaxin, Covishield vaccines.

The high court also asked the Centre to explain in affidavit the rationale behind keeping strict control over class of persons who can be vaccinated against COVID-19 currently as under the present system those above the age of 60 years or between 45 to 60 years with comorbidities can receive vaccination.

A bench of Justices Vipin Sanghi and Rekha Palli said the two institutes-- Serum Institute of India and Bharat Biotech -- have more capacity to provide the vaccines but it seems that they are not exploiting it fully.

"We are not utilising it fully. We are either donating it to foreign countries or selling it to foreign countries and are not vaccinating our own people. So there has to be that sense of responsibility and urgency," the bench said.

It also asked the Delhi government to carry out inspection of medical facilities available in court complexes here and to report if COVID-19 vaccination centres could be set up there.

The high court was hearing a PIL initiated by it to examine the demand of Bar Council of Delhi to declare all people associated with the judicial functioning, including judges, court staff and lawyers as frontline workers so that they could receive COVID-19 vaccination on priority and without limitations of their age or physical condition.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Coronavirus

First Published: Mar 04 2021 | 2:41 PM IST

Next Story